Abstract

Evaluate the effects of bromopride on abdominal wall healing of rats with induced peritoneal sepsis after segmental colectomy and colonic anastomosis. Forty rats underwent sectioning of the left colon and end-to-end anastomosis and were divided into two groups of 20 animals for the administration of bromopride (bromopride group - B) or saline solution (control group - C). Each group was divided into subgroups of 10 animals each to be killed on the third (GB3 and GC3) or seventh postoperative day (GB7 and GC7). It was analyzed the following characteristics: breaking strength of the abdominal wall's wound; surgical and histopathological features of the abdominal wall; and clinical features of the rats. There was no difference between the groups in relation to the weight of the rats and the breaking strength of the abdominal wall's wound. The GB7 group presented less edema and less quantity of fibrin during histopathological evaluation compared to the GC7 group. Bromopride did not have harmful effects on the healing of abdominal wall in rats.

Highlights

  • MethodsThe use of antiemetic drugs is common in the postoperative period since nausea and vomiting are the most common complications after surgical procedures and general anesthesia

  • One rat from the control group and one rat from the bromopride group, both to kill on the seventh day, were excluded from the study because they died in the immediate postoperative period with deaths not associated with the use of medications

  • It is important to say that this article analyzes the use of bromopride in a very specific condition: in the postoperative period of rats with induced peritoneal sepsis after segmental colectomy and colonic anastomosis

Read more

Summary

Introduction

The use of antiemetic drugs is common in the postoperative period since nausea and vomiting are the most common complications after surgical procedures and general anesthesia. There are fewer reports of extrapyramidal release using the bromopride than using other antidopaminergic drugs, such as metoclopramide. This fact does not reflect a minor side effect of bromopride but it reflects fewer studies about this drug than about metoclopramide[3]. It explains why bromopride is not sold in European countries and in the United States and confirms the need for experimental and clinical studies about this drug

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call